Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Average Bungyo Rate for All Programs Exceeds 40% for First Time
February 19, 2001
-
ARCHIVE Korosho Denies Need for Further Deregulation
February 19, 2001
-
ARCHIVE Sumitomo Revises Sales for 2002 Upward to \150 Billion: President Yokotsuka
February 19, 2001
-
ARCHIVE FPMAJ Drafts GL for Distinctive Labeling of Paper, Plastic Packages
February 19, 2001
-
ARCHIVE J&J Pushes Sales of Tylenol Series
February 19, 2001
-
ARCHIVE Fujisawa Aims at Top Share in Market for Psychotropics
February 19, 2001
-
ARCHIVE Guide to Prepare NDA Dossiers According to CTD Published
February 19, 2001
-
ARCHIVE Rohto to Introduce Sliming Supplement from Italy
February 19, 2001
-
ARCHIVE Santen Licenses in Anti-APO-1 Antibody from Centocor
February 19, 2001
-
ARCHIVE REGULATORY NEWS IN BRIEF -1-
February 19, 2001
-
ARCHIVE DyDo to Aggressively Expand Drugstore Business
February 19, 2001
-
ARCHIVE JT to Withdraw from OTC Business
February 19, 2001
-
ARCHIVE REGULATORY NEWS IN BRIEF -2-
February 19, 2001
-
ARCHIVE PAL Violations Found in 96 Pharmacies in 3 Years in Osaka
February 19, 2001
-
ARCHIVE Rush of New Drug Launches from Foreign Companies Continues
February 12, 2001
-
ARCHIVE CORPORATE ROUNDUP NEWS IN BRIEF -2-
February 12, 2001
-
ARCHIVE Pharmacists Should Serve as Risk Managers: SJP Seminar
February 12, 2001
-
ARCHIVE Taisho Licenses in Antiobesity Agents from Arena
February 12, 2001
-
ARCHIVE WORLD NEWS IN BRIEF
February 12, 2001
-
ARCHIVE REGULATORY NEWS IN BRIEF
February 12, 2001
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…